Marksans Pharma Limited
Marksans Pharma Limited Fundamental Analysis
Marksans Pharma Limited (MARKSANS.NS) shows moderate financial fundamentals with a PE ratio of 22.22, profit margin of 12.85%, and ROE of 14.49%. The company generates $28.1B in annual revenue with strong year-over-year growth of 20.46%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 71.9/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze MARKSANS.NS's fundamental strength across five key dimensions:
Efficiency Score
ExcellentMARKSANS.NS demonstrates superior asset utilization.
Valuation Score
ModerateMARKSANS.NS shows balanced valuation metrics.
Growth Score
ExcellentMARKSANS.NS delivers strong and consistent growth momentum.
Financial Health Score
ExcellentMARKSANS.NS maintains a strong and stable balance sheet.
Profitability Score
WeakMARKSANS.NS struggles to sustain strong margins.
Key Financial Metrics
Is MARKSANS.NS Expensive or Cheap?
P/E Ratio
MARKSANS.NS trades at 22.22 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, MARKSANS.NS's PEG of 9.09 indicates potential overvaluation.
Price to Book
The market values Marksans Pharma Limited at 2.98 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 13.69 times EBITDA. This signals the market has high growth expectations.
How Well Does MARKSANS.NS Make Money?
Net Profit Margin
For every $100 in sales, Marksans Pharma Limited keeps $12.85 as profit after all expenses.
Operating Margin
Core operations generate 22.01 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $14.49 in profit for every $100 of shareholder equity.
ROA
Marksans Pharma Limited generates $10.47 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Marksans Pharma Limited generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
Marksans Pharma Limited generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
MARKSANS.NS converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
22.22
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
9.09
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.98
vs 25 benchmark
P/S Ratio
Price to sales ratio
2.86
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.22
vs 25 benchmark
Current Ratio
Current assets to current liabilities
5.18
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.14
vs 25 benchmark
ROA
Return on assets percentage
0.10
vs 25 benchmark
ROCE
Return on capital employed
0.21
vs 25 benchmark
How MARKSANS.NS Stacks Against Its Sector Peers
| Metric | MARKSANS.NS Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 22.22 | 29.78 | Better (Cheaper) |
| ROE | 14.49% | 792.00% | Weak |
| Net Margin | 12.85% | -24634.00% (disorted) | Strong |
| Debt/Equity | 0.22 | 0.25 | Neutral |
| Current Ratio | 5.18 | 4.60 | Strong Liquidity |
| ROA | 10.47% | -18106.00% (disorted) | Strong |
MARKSANS.NS outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Marksans Pharma Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
109.82%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
184.73%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
-11.07%
Industry Style: Defensive, Growth, Innovation
Declining